Vertex Pharmaceuticals (VRTX) Interest Expenses (2009 - 2025)

Vertex Pharmaceuticals' Interest Expenses history runs 18 years deep, the most recent figure standing at $420.3 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 17.6% year-over-year to $420.3 million; the TTM figure through Mar 2026 stood at $420.3 million (up 17.6% YoY), while the FY2025 annual figure was $436.6 million, up 27.89% from the prior year.
• Interest Expenses for Q1 2026 stood at $420.3 million, up from $53.1 million in the prior quarter.
• The five-year high for Interest Expenses was $2.8 billion in Q3 2024, with the low at $11.0 million in Q4 2023.
• The 5-year median for Interest Expenses is $245.4 million (2023), against an average of $369.1 million.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 1038.88% in 2024, then plunged 84.91% in 2025.
• Vertex Pharmaceuticals' Interest Expenses stood at $13.7 million in 2022, then retreated by 19.71% to $11.0 million in 2023, then surged by 122.73% to $24.5 million in 2024, then surged by 116.73% to $53.1 million in 2025, then surged by 691.53% to $420.3 million in 2026.
• Business Quant data shows VRTX's Interest Expenses at $420.3 million in Q1 2026, $53.1 million in Q4 2025, and $421.6 million in Q3 2025.